Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis (SAPD)
Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis
Hypothesis:
Patients starting peritoneal dialysis with a glucose-based regimen have high sympathetic activity in response to an increase in leptin and insulin. Converting patients from a regimen of only glucose containing dialysate to a regimen with non-glucose-based solution, icodextrin, will reduce the insulin and leptin levels and will reverse dialysis-induced increases in sympathetic activity.
調査の概要
詳細な説明
Cardiovascular mortality remains higher among patients treated with peritoneal dialysis as compared to patients treated with hemodialysis. Sympathetic hyperactivity is considered a significant emerging risk factor for cardiovascular mortality among patients with ESRD (End-Stage Renal Disease). Sympathetic activity, via its hemodynamic effects and trophic effects, and in interaction with RAAS (Renin Angiotensin Aldosterone System), does play a major role in cardiac and vascular remodelling, development of LVH and vascular hypertrophy, as well as progression to CHF. Glucose-based dialysate induces hyperinsulinemia and hyperleptinemia. We propose that hyperleptinemia induced by glucose-based peritoneal solution is a significant contributing factor to sympathetic hyperactivity in ESRD patients treated with PD, and could be prevented by non-glucose-based PD solution such as icodextrin-based.
Adult patients with ESRD starting PD as their first renal replacement therapy modality will be studied. Patients will be recruited 1-3 weeks prior to starting PD treatment. At baseline, specific studies for microneurography (MSNA), fasting plasma insulin, leptin, catecholamines and brain natriuretic peptide (BNP) will be performed. EKG will be recorded and digitized for further assessment of heart rate variability using power spectral analysis. Extracellular fluid volume status will be assessed by bioelectrical impedance. Central vascular volume will be assessed from inferior vena cava (IVC) by heart ultrasound. Consequently 24-h ambulatory blood pressure monitoring(ABPM)and a 24-h urine collection for urea clearance and creatinine clearance will be done.
All participants into the study will receive a PD treatment for 6 weeks with standard glucose-based PD solution Dianeal. The specific studies are repeated at 6 weeks.Then, patients will be randomized to one of the two groups (arms). One group will continue with Dianeal PD solution for another 12 weeks. The other group will receive Dianeal during the day and Extraneal, icodextrin or non-glucose based solution, during the night only, for the next 12 weeks. The specific studies are repeated at 12 weeks after randomization (18 weeks of PD treatment).
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Ontario
-
Ottawa、Ontario、カナダ
- Ottawa Hospital Research Institute
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adult (age 18 years and older)
- Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5
Exclusion Criteria:
- Diabetes Mellitus
- Acute coronary syndrome in the past 6 months
- Cardiac arrhythmias (2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5)
- Symptoms suggestive of obstructive or central sleep apnea (with a score of > 10 on Epworth sleepiness scale)
- Patients taking Clonidine
- Body mass index (BMI) > 34
- Patients unable to give consent
- Pregnant women
- Patients with leg injury involving nerve damage
- Patients taking anticoagulant medication
- Patients with significant bleeding disorder or liver disorder
- Hemoglobin <1.05 g/dl at the time of initiation of therapy
- patients with unilateral or bilateral nephrectomy
- Planned kidney transplant in the next 4 months
- Life expectancy under 6 months
- Oliguria (urine output less than 400 ml per day)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:DIANEAL
One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
|
Weeks 1 to 6 (6 weeks):
Weeks 7 to 18 (12 weeks): *same regimen as weeks 1 to 6, for both CAPD and CCPD patients
他の名前:
|
アクティブコンパレータ:EXTRANEAL
The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
|
Weeks 1 to 6 (6 weeks):
Weeks 7 to 18 (12 weeks):
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Changes in muscle sympathetic nerve activity(MSNA)
時間枠:6 weeks on PD and 18 weeks on PD
|
Muscle sympathetic nerve activity(MSNA) is measured by microneurography at
MSNA increases on a glucose-based dialysis regimen and may decrease by adding non-glucose-based solution |
6 weeks on PD and 18 weeks on PD
|
Changes in leptin levels
時間枠:6 weeks on PD and 18 weeks on PD
|
Plasma leptin increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Changes in blood pressure as assessed from 24-hour ambulatory blood pressure monitor (ABPM)
時間枠:6 weeks on PD and 18 weeks on PD
|
Blood pressure will be assessed with 24-hour ABPM at baseline, 6 weeks on PD and 18 weeks after starting peritoneal dilaysis.
Summary measures of each day and night period include average systolic and diastolic BP as well as % nocturnal dipping.
These summary measures can predict cardiovascular events more accurately than casual BP measures
|
6 weeks on PD and 18 weeks on PD
|
Changes in extracellular volume assessed by bioelectrical impedance (BIA)
時間枠:6 weeks on PD and 18 weeks on PD
|
Bioelectrical impedance directly measures extracellular fluid volume and total body water.
The test is based on the ability to detect differences in the conductive properties of a cell by measuring its resistance (impedance) to electrical current.
The technique is reliable for tracking sequential changes in extracellular fluid volume.
|
6 weeks on PD and 18 weeks on PD
|
Changes in heart rate variability
時間枠:6 weeks on PD and 18 weeks on PD
|
During the microneurography testing, EKG is recorded.
Heart rate and heart rate variability(HRV) will be analyzed from EKG data at baseline, 6 weeks and 18 weeks after starting dialysis.
|
6 weeks on PD and 18 weeks on PD
|
Changes in central intravascular volume assessed by cardiac ultrasound
時間枠:6 weeks on PD and 18 weeks on PD
|
Central intravascular volume will be assessed by measuring inferior vena cava (IVC) diameter during cardiac ultrasound at baseline, 6 weeks and 18 weeks on dialysis treatment
|
6 weeks on PD and 18 weeks on PD
|
Changes in plasma catecholamines levels
時間枠:6 weeks on PD and 18 weeks on PD
|
*Plasma catecholamines (epinephrine and norepinephrine) increase on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
Changes in BNP (Brain Natriuretic Peptide)levels
時間枠:6 weeks on PD and 18 weeks on PD
|
*Brain Natriuretic Peptide (BNP)increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
Changes in plasma insulin levels
時間枠:6 weeks on PD and 18 weeks on PD
|
*Plasma insulin increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
協力者と研究者
捜査官
- 主任研究者:Marcel Ruzicka, MD, PHD、Ottawa Hospital Research Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
DIANEALの臨床試験
-
Iperboreal Pharma Srl募集